New Integrated Continuous Glucose Monitor Available to Patients With Diabetes
A new integrated continuous glucose monitoring system that aims to help patients with diabetes manage their condition and to share health data with care providers is now available.
The FreeStyle Libre 2 iCGM aims to help patients with diabetes manage their condition and to share health data with care providers.
Abbott’s FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) systemis now available, according to the company.1 The system is available by prescription at participating pharmacies and durable medical equipment suppliers across the United States.2
The device was approved by the FDA in June 2020.1,2 It is indicated for adults and children ages 4 years and older with diabetes.2
The FreeStyle Libre 2 next-generation sensor is worn on the back of the upper arm for 14 days is a third less bulky than other CGM sensors, according to Abbott. It allows patients with diabetes to view their glucose reading, trend arrow, and 8-hour history with a 1-second scan through a handheld reader.2
This new system is designed to help people manage their condition, and it facilitates sharing health data with their doctors. According to Abbott, this technology is critical to achieving better outcomes and more efficient, safe telehealth visits.1
Abbott is offering the new system at the same price as the previously made available FreeStyle Libre 14-day system, a cost that is about 70% less than other CGMs currently available, according to the company.1
REFERENCES
- Murphy C. Abbott’s FreeStyle Libre 2 is Now Available. Abbott email. Sent July 30, 2020. Accessed August 4, 2020.
- Coppock K. FDA Approves FreeStyle Libre 2 iCGM System for Patients With Diabetes. Pharmacy Times. pharmacytimes.com/news/fda-approves-freestyle-libre-2-icgm-system-for-patients-with-diabetes. Published June 15, 2020. Accessed August 4, 2020.
